Nuwellis reports strong 2026 console sales and 26% U.S. revenue growth, positioning the company for a potential record-setting year in equipment placement and future recurring consumable revenue.
Nuwellis reported 31 Aquadex console sales year-to-date in 2026 and 26% U.S. revenue growth, signaling expanding installed base and potential future recurring consumable revenue.
Nuwellis (NUWE) reports 31 Aquadex console sales year-to-date in 2026, outpacing annual totals from seven of the last ten years. This expansion in the installed base, coupled with 26% U.S. revenue growth in the first half, signals strong commercial momentum across pediatrics, critical care, and heart failure markets.
Nuwellis generates recurring revenue through the sale of single-use blood circuits and disposables required for each treatment performed on the Aquadex console.